With FDA review of its gene therapy underway, Ferring's $570M spinout delivers in PhIII bladder cancer readout
FerGene was born ready. By the time Ferring spun out the biotech with a gene therapy licensed from FKD Therapies Oy and $400 million in cash from Blackstone, they had secured a priority review on their BLA and pointed to an imminent date for the pivotal Phase III readout in bladder cancer.
The date came yesterday, and FerGene said its experimental drug did not disappoint.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 70,500+ biopharma pros reading Endpoints daily — and it's free.